Tuesday, 12 January 2010 at 11:16, Bloomberg
GlaxoSmithKline Plc will seek US approval of its experimental lupus drug, Benlysta, in the first half of the year, Chief Executive Officer Andrew Witty said. London-based Glaxo is developing Benlysta with Rockville, Maryland-based Human Genome Science Inc Witty made his remarks today at the JPMorgan healthcare conference in San Francisco.
Your comments